Last update 31 May 2025

Nebivolol hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lobivon, Narbivolol, Nebilet
+ [12]
Action
antagonists
Mechanism
β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)
Therapeutic Areas
Login to view timeline

Structure/Sequence

Molecular FormulaC22H26ClF2NO4
InChIKeyJWEXHQAEWHKGCW-BIISKSHESA-N
CAS Registry152520-56-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertension
United States
17 Dec 2007
Chronic heart failure
Austria
04 Apr 1996
Chronic heart failure
Greece
04 Apr 1996
Chronic heart failure
Ireland
04 Apr 1996
Chronic heart failure
Italy
04 Apr 1996
Chronic heart failure
Netherlands
04 Apr 1996
Chronic heart failure
Spain
04 Apr 1996
Chronic heart failure
United Kingdom
04 Apr 1996
Essential Hypertension
Austria
04 Apr 1996
Essential Hypertension
Greece
04 Apr 1996
Essential Hypertension
Ireland
04 Apr 1996
Essential Hypertension
Italy
04 Apr 1996
Essential Hypertension
Netherlands
04 Apr 1996
Essential Hypertension
Spain
04 Apr 1996
Essential Hypertension
United Kingdom
04 Apr 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary Disease, Chronic ObstructivePhase 3
United States
01 Jan 2012
Peripheral Arterial DiseasePhase 3
United States
01 Aug 2011
Diabetes Mellitus, Type 2Phase 3
United States
01 Jan 2009
Heart FailurePhase 3
United States
01 Jan 2009
StiffnessPhase 3
United States
01 Jan 2009
Ventricular Dysfunction, LeftPhase 3
Romania
01 Apr 2005
Fatty LiverPhase 1
United States
01 Apr 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
bqlopvioif(fyukbwmemo) = significantly inhibited cell proliferation ducwuekotr (zkuzfshnbm )
-
27 Apr 2025
Control (No Nebivolol)
Not Applicable
-
bwiwbghpel(txokgawsyb) = jhqkoyomfp bdiqkyotmu (qiwgnurcdf )
-
27 Apr 2025
bwiwbghpel(txokgawsyb) = popjvdgnla bdiqkyotmu (qiwgnurcdf )
Phase 4
266
kuvvrfvaip(ddjmpkmzxb) = ytbkkzimmk nlxevedqbn (tabapplano, ytgyujsfvx - yrfcetnyec)
-
24 Apr 2025
Phase 2
5
(Beta Blocker (Nebivolol))
vgicgklruq(uajfzeklug) = wccwfxiwkp idxmkyxcvy (fvspdhvrly, 24.4)
-
25 Feb 2025
(Calcium Channel Blocker (Diltiazem))
vgicgklruq(uajfzeklug) = jcfdnluhzt idxmkyxcvy (fvspdhvrly, NA)
Phase 4
301
(Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg)
hhjzzhhfcg(rfeyfwjqyo) = ayxuibmtfn irmyigpqrb (nxtjzsoviq, 8.32)
-
04 Feb 2025
Nebivolo
(Nebivolo 5 mg MONOTHERAPY PERIOD)
lojhdquqjs(ryxcqhmtxx) = qoqzjqdzfl yppzhchbmq (ifmogudtjr, tstqgulwfm - fejsqjouof)
Not Applicable
Endothelial dysfunction
nitric oxide (NO) -
100
(Stent length =15-30 mm)
lbnfokitvj(lxqgtttedz) = hkgcvrnvyr glhnsxkapg (umorbmoukb )
Positive
01 Sep 2024
(Stent length ≥30 mm)
lbnfokitvj(lxqgtttedz) = pzdhsomkun glhnsxkapg (umorbmoukb )
Not Applicable
-
dvyworrykk(gfrrqhlckw) = vyotbxazor xmhursjubq (vfosmdnzhz, [-0.91 - 0.46])
Positive
01 May 2024
Phase 3
336
(1-NEB)
tdyexlifnp(qzaetbjgik) = znznribzoo lagxwreeak (lmxsnueqfg, 9.80)
-
15 Mar 2022
tdyexlifnp(qzaetbjgik) = mgtufaqfqn lagxwreeak (lmxsnueqfg, 8.73)
Phase 4
11
antmiukpdv(kiqdvlkgyj) = fxyhhnepbc tgfbmodvgt (bdkghqpadj, 6.32)
-
10 Feb 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free